Literature DB >> 2155604

Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.

J E Souness1, B K Diocee, W Martin, S A Moodie.   

Abstract

Two cyclic nucleotide phosphodiesterase (PDE) activities were identified in pig aortic endothelial cells, a cyclic GMP-stimulated PDE and a cyclic AMP PDE. Cyclic GMP-stimulated PDE had Km values of 367 microM for cyclic AMP and 24 microM for cyclic GMP, and low concentrations (1 microM) of cyclic GMP increased the affinity of the enzyme for cyclic AMP (Km = 13 microM) without changing the Vmax. This isoenzyme was inhibited by trequinsin [IC50 (concn. giving 50% inhibition of substrate hydrolysis) = 0.6 microM for cyclic AMP hydrolysis in the presence of cyclic GMP; IC50 = 0.6 microM for cyclic GMP hydrolysis] and dipyridamole (IC50 = 5 microM for cyclic AMP hydrolysis in the presence of cyclic GMP; IC50 = 3 microM for cyclic GMP hydrolysis). Cyclic AMP PDE exhibited a Km of 2 microM for cyclic AMP and did not hydrolyse cyclic GMP. This activity was inhibited by trequinsin (IC50 = 0.2 microM), dipyridamole (IC50 = 6 microM) and, selectively, by rolipram (IC50 = 3 microM). Inhibitors of cyclic GMP PDE (M&B 22948) and of low Km (Type III) cyclic AMP PDE (SK&F 94120) only weakly inhibited the two endothelial PDEs. Incubation of intact cells with trequinsin and dipyridamole induced large increases in cyclic GMP, which were completely blocked by LY-83583. Rolipram, SK&F 94120 and M&B 22948 did not significantly influence cyclic GMP accumulation. Dipyridamole enhanced the increase in cyclic GMP induced by sodium nitroprusside. Cyclic AMP accumulation was stimulated by dipyridamole and trequinsin with and without forskolin. Rolipram, although without effect alone, increased cyclic AMP in the presence of forskolin, whereas M&B 22948 and SK&F 94120 had no effects on resting or forskolin-stimulated levels. These results suggest that cyclic GMP-stimulated PDE regulates cyclic GMP levels and that both endothelial PDE isoenzymes contribute to the control of cyclic AMP.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155604      PMCID: PMC1131105          DOI: 10.1042/bj2660127

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  21 in total

Review 1.  Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme.

Authors:  W J Thompson; W L Terasaki; P M Epstein; S J Strada
Journal:  Adv Cyclic Nucleotide Res       Date:  1979

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  LY 83583 interferes with the release of endothelium-derived relaxing factor and inhibits soluble guanylate cyclase.

Authors:  A Mülsch; R Busse; S Liebau; U Förstermann
Journal:  J Pharmacol Exp Ther       Date:  1988-10       Impact factor: 4.030

4.  Federation of American Societies for Experimental Biology. 72nd annual meeting. Las Vegas, Nevada, May 1-5, 1988. Abstracts of papers 1-3785.

Authors: 
Journal:  FASEB J       Date:  1988-03-15       Impact factor: 5.191

5.  Prostacyclin releases endothelium-derived relaxing factor and potentiates its action in coronary arteries of the pig.

Authors:  H Shimokawa; N A Flavahan; R R Lorenz; P M Vanhoutte
Journal:  Br J Pharmacol       Date:  1988-12       Impact factor: 8.739

Review 6.  Action of mediators on airway smooth muscle: functional antagonism as a mechanism for bronchodilator drugs.

Authors:  T J Torphy
Journal:  Agents Actions Suppl       Date:  1988

7.  Effects of PGI2 and PGI analogues on cAMP levels in cultured endothelial and smooth muscle cells derived from bovine arteries.

Authors:  A Dembinska-Kiec; W Rücker; P S Schönhöfer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-02       Impact factor: 3.000

8.  Atrial natriuretic factor reduces cyclic adenosine monophosphate content of human fibroblasts by enhancing phosphodiesterase activity.

Authors:  M A Lee; R E West; J Moss
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

9.  Stimulation of cyclic AMP production by vasoactive agents in cultured bovine aortic and pulmonary artery endothelial cells.

Authors:  J S Makarski
Journal:  In Vitro       Date:  1981-05

10.  Plaque formation and isolation of pure lines with poliomyelitis viruses.

Authors:  R DULBECCO; M VOGT
Journal:  J Exp Med       Date:  1954-02       Impact factor: 14.307

View more
  12 in total

1.  The impact of commercially available purinergic ligands on purinergic signalling research.

Authors:  J R Flanaghan; S J Roome
Journal:  Purinergic Signal       Date:  2011-10-27       Impact factor: 3.765

Review 2.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Role of cyclic AMP in promoting the thromboresistance of human endothelial cells by enhancing thrombomodulin and decreasing tissue factor activities.

Authors:  G Archipoff; A Beretz; K Bartha; C Brisson; C de la Salle; C Froget-Léon; C Klein-Soyer; J P Cazenave
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

4.  Hyperpermeability of pulmonary endothelial monolayer: protective role of phosphodiesterase isoenzymes 3 and 4.

Authors:  N Suttorp; P Ehreiser; S Hippenstiel; M Fuhrmann; M Krüll; H Tenor; C Schudt
Journal:  Lung       Date:  1996       Impact factor: 2.584

5.  cAMP-specific phosphodiesterase inhibitor, rolipram, reduces eosinophil infiltration evoked by leukotrienes or by histamine in guinea pig conjunctiva.

Authors:  S J Newsholme; L Schwartz
Journal:  Inflammation       Date:  1993-02       Impact factor: 4.092

6.  Role of phosphodiesterases in the regulation of endothelial permeability in vitro.

Authors:  N Suttorp; U Weber; T Welsch; C Schudt
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

7.  Effects of two vasodilatory phosphodiesterase inhibitors on bradykinin-induced permeability increase in the hamster cheek pouch.

Authors:  E Svensjö; K E Andersson; E Bouskela; F Z Cyrino; S Lindgren
Journal:  Agents Actions       Date:  1993-05

8.  Role of phosphodiesterase isoenzymes in regulating intracellular cyclic AMP in adenosine-stimulated smooth muscle cells.

Authors:  Y Xiong; E W Westhead; L L Slakey
Journal:  Biochem J       Date:  1995-01-15       Impact factor: 3.857

9.  Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.

Authors:  A E Eckly; C Lugnier
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

10.  Cytochemical distribution of cyclic AMP-dependent 3',5'-nucleotide phosphodiesterase in the rat myocardium.

Authors:  L Okruhlicová; N Tribulová; A Eckly; C Lugnier; J Slezák
Journal:  Histochem J       Date:  1996-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.